Samples of drugs used in diabetes, hypertension, allergies, infections found substandard in quality tests

Jaipur: Samples of five drugs were found to be of substandard quality upon testing and analysis conducted by the Commissionerate, Food Safety and Drug Control (CFSDC).

On Wednesday, the CFSDC issued directions to all the district drug controllers in the state to ensure that the stocks of these drugs are no longer consumed. They were instructed to provide appropriate safeguards to consumers by withdrawing the available stock and taking action as per the provisions of the Drugs & Cosmetics Act 1940.

A senior CFSDC official said, samples of Levocetirizine Dihydrochloride Tablets (Wincet-L), manufactured by M/s YL Pharma of Baddi in Solan district, Himachal Pradesh, were found to be of substandard quality. The drug was sold as an antihistamine used to treat symptoms associated with various allergic conditions.

A sample of Voglibose tablets 0.3 mg (DULCOVOG-0.3), manufactured by M/s Lifecare Neuro Products Ltd of Dharampur in Himachal Pradesh, failed the quality test. The drug is used as an antidiabetic medication to manage type 2 diabetes mellitus.
A sample of Ofloxacin Tablets IP 200 mg (OFWIN-200), manufactured by M/s YL Pharma of Baddi in Solan, failed the quality test. The drug is a fluoroquinolone antibiotic used to treat a variety of bacterial infections.

A sample of Telmisartan and Amlodipine Tablets IP (Telpin-A), manufactured by India M/s Maskon Life Sciences Pvt. Ltd in Bhagwanpur of Roorkee, was found to be of substandard quality. The drug is used as a combination medication to treat high blood pressure (hypertension) in adults.

The CFSDC tested a sample of Cefixime Oral Suspension manufactured by M/s Agron Remedies Pvt. Ltd of Sarverkhera, Uttarakhand, which failed the quality test. It is used as an antibiotic medication to treat a variety of bacterial infections, particularly in children and adults who have difficulty swallowing pills.

Related Posts

Unapproved drops for dry eyes pose risks: Govt

NEW DELHI: Flagging that certain yet-to-be-approved dry eye relief drops are being sold in the market, the central drugs regulator has asked states to cancel any permissions granted for these…

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Unapproved drops for dry eyes pose risks: Govt

Unapproved drops for dry eyes pose risks: Govt

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Govt highlights multi-layer framework to curb misleading advertisements

Govt highlights multi-layer framework to curb misleading advertisements

Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

Study finds rising resistance to a last-resort antibiotic in Africa

Study finds rising resistance to a last-resort antibiotic in Africa